
Biofol5 mg
Incepta Pharmaceuticals Ltd.
Calcium Folinate [Folinic Acid] (leucovorin, a reduced folate) is indicated for the following uses, classified by strength of evidence: Established / Approved Uses Leucovorin rescue after high-dose…
Calcium Folinate [Folinic Acid] (leucovorin, a reduced folate) is indicated for the following uses, classified by strength of evidence:
Calcium Folinate [Folinic Acid] is not effective, and must not be used, as a treatment for pernicious anemia or other vitamin B12-deficiency anemias (see Contraindications).
Dosing of Calcium Folinate [Folinic Acid] is highly indication-specific and must always follow the treating physician's protocol; the following is general reference information, not a substitute for individualized medical guidance.
| Indication | Typical Adult Dosing |
|---|---|
| Methotrexate rescue after high-dose methotrexate | Usually 15 mg (approx. 10 mg/m²) by mouth, intramuscularly, or intravenously every 6 hours, beginning approximately 24 hours after the start of the methotrexate infusion, and continued (with dose/frequency adjusted per serum methotrexate level) until the methotrexate level falls below the threshold specified in the treatment protocol (commonly less than 0.05–0.1 micromol/L). Exact timing is protocol- and hospital-specific. |
| Folic acid antagonist overdosage (e.g., methotrexate, trimethoprim, pyrimethamine) | As soon as possible, generally starting at approximately 10 mg/m² by mouth, intramuscularly, or intravenously, then every 6 hours until the serum methotrexate (or antifolate) level falls to a safe threshold; dose is adjusted upward if methotrexate elimination is delayed. |
| Megaloblastic anemia due to folate deficiency (when oral folic acid is not appropriate) | Up to 1 mg per day, intramuscularly, until the clinical situation permits switching to oral folic acid. |
| Adjunct to 5-fluorouracil in advanced colorectal cancer | Given as part of established combination regimens, for example 200 mg/m² or 20 mg/m² by slow intravenous injection, followed by 5-fluorouracil, on a schedule (commonly daily for 5 days, repeated in cycles) determined by the treating oncologist. Regimen and dose vary by protocol. |
Calcium Folinate [Folinic Acid] is administered by the intravenous, intramuscular, or oral route depending on the formulation and clinical situation. Calcium Folinate [Folinic Acid] must never be administered intrathecally — intrathecal administration has caused fatalities. When given intravenously, the rate of administration should not exceed the maximum recommended rate (due to the calcium content of the injection) as specified in the product label. See Reconstitution for preparation of the injectable powder form.
When used alone, Calcium Folinate [Folinic Acid] is generally well tolerated. Reported side effects include:
When Calcium Folinate [Folinic Acid] is combined with 5-fluorouracil chemotherapy, the following adverse effects are more frequent and can be more severe (these are largely attributable to enhanced 5-FU toxicity, not to Calcium Folinate [Folinic Acid] alone):
Patients should seek prompt medical attention for signs of a severe allergic reaction, severe diarrhea, mouth sores, unusual bleeding/bruising, fever, or signs of infection during combination chemotherapy.
Calcium Folinate [Folinic Acid] is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.